Market Closed -
Nasdaq
16:30:01 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
20.63
USD
|
+0.19%
|
|
+4.99%
|
+43.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
623.1
|
2,157
|
931.8
|
847.2
|
1,068
|
1,572
|
-
|
-
|
Enterprise Value (EV)
1 |
393.7
|
1,838
|
841.1
|
804.5
|
1,068
|
1,572
|
1,572
|
1,572
|
P/E ratio
|
-9.11
x
|
-19.3
x
|
-7.11
x
|
-6.11
x
|
-6.91
x
|
-8.16
x
|
-8.1
x
|
-8.47
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
124
x
|
17
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
124
x
|
17
x
|
EV / EBITDA
|
-9.23
x
|
-23.5
x
|
-7.13
x
|
-6.09
x
|
-6.47
x
|
-6.51
x
|
-6.61
x
|
-5.31
x
|
EV / FCF
|
-11.4
x
|
-30
x
|
-8.82
x
|
-7.65
x
|
-8.54
x
|
-8.16
x
|
-7.56
x
|
-8.16
x
|
FCF Yield
|
-8.79%
|
-3.34%
|
-11.3%
|
-13.1%
|
-11.7%
|
-12.3%
|
-13.2%
|
-12.3%
|
Price to Book
|
2.64
x
|
2.84
x
|
1.83
x
|
1.98
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
45,315
|
66,035
|
66,556
|
68,264
|
74,272
|
76,181
|
-
|
-
|
Reference price
2 |
13.75
|
32.66
|
14.00
|
12.41
|
14.38
|
20.63
|
20.63
|
20.63
|
Announcement Date
|
20-02-25
|
21-02-24
|
22-02-24
|
23-02-23
|
24-02-27
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
12.66
|
92.23
|
EBITDA
1 |
-67.48
|
-91.9
|
-130.7
|
-139.1
|
-165
|
-241.5
|
-237.8
|
-296
|
EBIT
1 |
-67.48
|
-91.9
|
-131.3
|
-139.9
|
-165.8
|
-223.3
|
-240
|
-233
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,896.36%
|
-252.66%
|
Earnings before Tax (EBT)
1 |
-63.14
|
-89.62
|
-130.5
|
-135.8
|
-152.6
|
-219.5
|
-235.3
|
-225.5
|
Net income
1 |
-63.14
|
-89.62
|
-130.5
|
-135.8
|
-152.6
|
-209.2
|
-229.5
|
-230.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,813.28%
|
-249.67%
|
EPS
2 |
-1.510
|
-1.690
|
-1.970
|
-2.030
|
-2.080
|
-2.529
|
-2.545
|
-2.437
|
Free Cash Flow
1 |
-54.76
|
-72
|
-105.7
|
-110.7
|
-125
|
-192.7
|
-208
|
-192.7
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,643.19%
|
-208.9%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-25
|
21-02-24
|
22-02-24
|
23-02-23
|
24-02-27
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-41.37
|
-33.68
|
-32.87
|
-32.6
|
-35.15
|
-36.4
|
-34.95
|
-36.36
|
-39.79
|
-42.26
|
-46.55
|
-47
|
-50.5
|
-51.3
|
-53.4
|
-
|
EBIT
1 |
-
|
-33.68
|
-33.04
|
-32.78
|
-35.33
|
-36.59
|
-35.16
|
-36.57
|
-40
|
-42.47
|
-46.76
|
-54.45
|
-54.54
|
-56.69
|
-59.18
|
-56.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-33.37
|
-32.74
|
-32.45
|
-34.77
|
-35.5
|
-33.11
|
-34.07
|
-37.17
|
-38.6
|
-42.79
|
-49.52
|
-54.22
|
-56.5
|
-59.23
|
-58.2
|
Net income
1 |
-
|
-33.37
|
-32.74
|
-32.45
|
-34.77
|
-35.5
|
-33.11
|
-34.07
|
-37.17
|
-38.6
|
-42.79
|
-49.52
|
-51.52
|
-53.53
|
-55.75
|
-55.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.5000
|
-0.4900
|
-0.4900
|
-0.5200
|
-0.5300
|
-0.4900
|
-0.5000
|
-0.5300
|
-0.5000
|
-0.5500
|
-0.5900
|
-0.6264
|
-0.6473
|
-0.6670
|
-0.6500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-08-06
|
21-11-04
|
22-02-24
|
22-05-04
|
22-08-03
|
22-11-03
|
23-02-23
|
23-05-10
|
23-08-03
|
23-11-02
|
24-02-27
|
24-05-02
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
229
|
318
|
90.7
|
42.6
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-54.8
|
-72
|
-106
|
-111
|
-125
|
-193
|
-208
|
-193
|
ROE (net income / shareholders' equity)
|
-33.3%
|
-21.6%
|
-23.3%
|
-29.3%
|
-37.3%
|
-60%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-29.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
212.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
5.220
|
11.50
|
7.640
|
6.270
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-1.310
|
-1.320
|
-1.580
|
-1.640
|
-1.610
|
-2.540
|
-2.100
|
1.550
|
Capex
1 |
-
|
2.17
|
1.15
|
0.63
|
0.17
|
1.6
|
1.93
|
1.93
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
15.27%
|
2.1%
|
Announcement Date
|
20-02-25
|
21-02-24
|
22-02-24
|
23-02-23
|
24-02-27
|
-
|
-
|
-
|
Last Close Price
20.63
USD Average target price
30.25
USD Spread / Average Target +46.63% Consensus |
1st Jan change
|
Capi.
|
---|
| +43.46% | 1.57B | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|